-
The first patient enrolled in the clinical trial of the innovative drug MDM2-p53 antagonist for the treatment of DDLPS in China
Time of Update: 2023-02-03
On January 5, 2023, Boehringer Ingelheim announced that its innovative drug MDM2-p53 antagonist BI 907828 for the first-line treatment of dedifferentiated liposarcoma (DDLPS) Phase II. /III. clinical
-
The national R&D project led by Southwest Institute was approved
Time of Update: 2023-02-02
The project participation is the advantage of domestic carbon dioxide catalytic conversion research and development, and relies on innovation platforms such as the State Key Laboratory of Comprehensive Utilization of Industrial Emissions, the Joint Key Laboratory of Chemical Engineering, the State Key Laboratory of Basic Catalysis, the National Carbon One Chemical Engineering Technology Research Center, and the Beijing National Research Center for Molecular Science.
-
Shanghai aluminum intraday strong operation market on-demand procurement
Time of Update: 2022-12-20
Today's Shanghai aluminum is running strongly, manufacturing activities in Europe and the United States have expanded, the economy has seen some recovery, domestic social inventories have accumulated, and short-term aluminum prices have fluctuated.
-
Shanghai aluminum intraday strong operation market on-demand procurement
Time of Update: 2022-12-20
Today's Shanghai aluminum is running strongly, manufacturing activities in Europe and the United States have expanded, the economy has seen some recovery, domestic social inventories have accumulated, and short-term aluminum prices have fluctuated.
-
Bacterial solar microfluidic panels provide long-lasting power supply
Time of Update: 2022-11-21
Bacterial solar cells Currently, one of the new bio-solar research focuses is to harness cyanobacteria found in almost every terrestrial and aquatic habitat on Earth as a sustainable energy resource.
-
Immunity: Designing and validating promising HIV vaccine strategies
Time of Update: 2022-10-20
One last step Scientists at the Scripps Institute and IAVI, in collaboration with the lab of Dr. Facundo Batista, associate director of the Lagan Institute, showed that the new immunogen was able to successfully bind germline precursor B cells and elicit the desired response in mice expressing bnAb germline genes at the same frequency as they would appear in humans.
-
ESMO directly attacks the immunoneoadjuvant therapy vs adjuvant therapy, and the perioperative exploration of melanoma
Time of Update: 2022-10-03
The first data presented at this ESMO conference from the Phase II SWOG S1801 study evaluated the use of neoadjuvant therapy (NAT) versus adjuvant therapy (AT) for resectable patients with stage III-IV melanoma.
-
The development of new drugs has accelerated, and recent clinical trials of many drugs have ushered in new progress
Time of Update: 2022-09-20
The clinical trial of BUCHANG Pharmaceutical BC008-1A injection drug was approved Recently, Buchang Pharmaceutical announced that its subsidiary has obtained a notice of approval for clinical trials of BC008-1A injection drugs, and the main indication of the drug is advanced solid tumor.
-
The country's first/set of Lumms process polypropylene polymerization reactor was completed and localized
Time of Update: 2022-08-28
On July 20, the reporter learned from Lanzhou Science and Technology Association that the polypropylene polymerization reactor with an annual output of 300,000 tons designed and manufactured by Tianhu
-
4.448 billion
Time of Update: 2022-08-18
66 billion, including: 250,000 tons/year ABS, 200,000 tons/year PIA, 600,000 tons/year PTA, 14/87,000 tons/year Annual PhOH/ACTN, 72,000 tons/year PP, 600,000 tons/year propylene Since 2016, Formosa Plastics affiliated companies have invested in a new upgrade plan, with an estimated total investment of US$1.
-
Baiyunshan's cash flow has increased by 9 times, and the joint mining price of the eight provinces has been cut by more than 90
Time of Update: 2022-04-16
(National Medical Insurance Administration) Market tide Unnamed medicine faces the risk of termination of listing On March 21, the Shenzhen Stock Exchange issued a letter of concern about Shandong Weiming Biology.
-
mRNA expression triple immunoregulatory factor Moderna immunotherapy shows preliminary anti-cancer activity
Time of Update: 2022-01-01
A few days ago, Moderna announced the preliminary phase 1 clinical trial results of its mRNA immunotherapy mRNA-2752 for the treatment of solid tumors and lymphoma patients .
-
TJBio announces that its bispecific antibody TJ-CD4B has been approved for Phase 1 clinical trials in China
Time of Update: 2021-12-27
On December 16, 2021, Horizon Biotech announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has officially approved the bispecific antibody TJ-CD4B (also known as ABL111) for the treatment of solid tumors (including gastric cancer, Phase 1 clinical study of esophageal-gastric junction adenocarcinoma, esophageal adenocarcinoma and pancreatic duct adenocarcinoma .
-
Express for drug-resistant bacterial infections, innovative antibiotic compound therapy Phase 3 clinical results are positive
Time of Update: 2021-11-04
▎Editor of WuXi AppTec content team On October 19, 2021, Zai Lab and Entasis Therapeutics announced that the antibiotic combination therapy sulbactam-durlobactam (SUL-DUR) has obtained positive results in a phase 3 clinical trial .
-
After Aducanumab was approved, the development of new drugs for Alzheimer's disease is surging
Time of Update: 2021-08-16
Text | Pickup BayOn June 7, the FDA accelerated the approval of Biogen/Eisai’s Aβ (amyloid β) antibody Aduhelm (aducanumab) for the treatment of Alzheimer’s disease (AD) patients with a biological product license (BLA) based on the biomarker surrogate endpoint.
